The aim of this experiment was to study the effects of erythropoietin on rat model, particularly in ischemia reperfusion protocol. The beneficial or other effects of that molecule were studied estimating the mean blood progesterone levels.
INTRODUCTION
Tissue ischemia and reperfusion (IR) remain one of the main causes of permanent or transient damage with serious implications on adjacent organs and certainly on patients' health. The use of erythropoietin (EPO) is a well established knowledge for many years. However despite important progress has been made, satisfactory answers have not been obtained yet to the fundamental questions, such as by what velocity this factor acts, when should it be administered, and in what dosage. The particularly satisfactory action of the erythropoietin in stem blood cells recovery has been noted in several performed experiments. Since a careful literature search (PubMed-Medline) was conducted, it was realized that this certain factor has been tried in experiments. However, just few relative reports were found, not covering completely this particular object of action velocity. A lot of publications are present on trials of other similar molecules of growth factors to which the studied molecule also belongs to.
The aim of this experimental study was to examine the effect of the drug EPO on rat model and particularly in an ovarian IR protocol. The beneficial effect or noneffectiveness of that molecule were studied by measuring blood progesterone levels.
MATERIALS AND METHODS

Animal Preparation
This experimental study was approved by Scientific committee of Ippokrateion General Hospital, Athens University and by Veterinary Address of East Attiki Prefecture under 3693/12-11-2010 and 14/10-1-2012 decisions. Institutional and national guide for the care and use of laboratory animals was followed. This experimental study was carried out at the Exprerimental Research Center of ELPEN Pharmaceuticals Co. Inc. SA at Pikermi, Attiki. All settings needed for the study including of consumables, equipment and substances used, were provided by them. Albino female Wistar rats were used in accordance with accepted standards of humane animal care. They spent 7 days in laboratory before experimentation with easy access to water and food. The experiment was acute, that is, the animal usage was completed by following experimental set of times without awakening and preservation of the rodents. They were randomly assigned to four experimental groups (10 animals in each group). Group A: Ischemia for 45 minutes followed by reperfusion for 60 minutes. Group B: Ischemia for 45 minutes followed by reperfusion for 120 minutes. Group C: Ischemia for 45 minutes followed immediately by EPO intravenous (IV) administration and reperfusion for 60 minutes. Group D: Ischemia for 45 minutes followed immediately by EPO IV administration and reperfusion for 120 minutes.
The molecule erythropoietin was administered in a dose of: 10 mg/kg body weight of the animal.
The experiment was beginning by prenarcosis and general anesthesia administration to the animals. Their electrocardiogram and acidometry were continuously monitored. The inferior aorta was prepared so as its blood flow could be excluded by forceps. After exclusion, the protocol of IR was applied, exactly as is described in experimental groups. The molecules were administered at the time of reperfusion, through inferior vena cava catheterization, which had been carried out after general anesthesia.
The progesterone levels measurements were performed at 60 minutes after reperfusion for groups A and C and at 120 minutes after reperfusion for groups B and D.
Protocol of the Experiment
The experimental rats were given general anesthesia by initial intramuscular (IM) administration of 0.5 cc of a compound, constituting 0.25 cc xylazine, (25 cc, 20 mg/cc) and 0.25 cc ketamine hydrochloride (1000, 100 mg/cc, 10 cc). 0.03 cc butorphanol (10 mg/cc, 10 cc) anesthetic agent was administered subcutaneously (SC) before laparotomy. Continuous oxygen supply was administered during the whole experiment. Ischemia was caused by clamping inferior aorta over renal arteries for 45 minutes after laparotomic access. Reperfusion was achieved by removing the clamp and inferior aorta patency re-establishment. Forty (40) female Wistar albino rats were used of mean weight 247.7 gm (std. dev: 34.99172 gm), with minutes weight ≥ 165 gm and max weight ≤ 320 gm. Rats' weight could be potentially a confusing factor, e.g. fatter rats to have greater blood progesterone levels. This suspicion will be investigated.
MODEL OF ISCHEMIA-REPERFUSION INJURY
Control Groups
Twenty control rats of mean weight 252.5 gm (std. dev: 39.31988 gm) were subjected to ischemia for 45 minutes followed by reperfusion.
Group A: Ten controls rats of mean weight 243 gm (std. dev: 45.77724 gm), mean progesterone levels 36.94 nmol/l (std. dev: 35.57759 nmol/l) were subjected to 60 minutes reperfusion (Table 1) .
Group B: Ten controls rats of mean weight 262 gm (std. dev: 31.10913 gm), mean progesterone levels 39.816 nmol/l (std. dev: 21.82161 nmol/l) were subjected to 120 minutes reperfusion (see Table 1 ).
Erythropoietin Group
Twenty rats of mean weight 242.9 gm (std. dev: 30.3105 gm) were subjected to ischemia for 45 minutes followed by reperfusion in the beginning of which 10 mg EPO/kg body weight were IV administered.
Group C: Ten EPO rats of mean weight 242.8 gm (std. dev: 29.33636 gm), mean progesterone levels 44.255 nmol/l (std. dev: 25.23905 nmol/l) were subjected to 60 minutes reperfusion (see Table 1 ).
Group D: Ten EPO rats of mean weight 243 gm (std. dev: 32.84644 gm), mean progesterone levels 40.972 nmol/l (std. dev: 26.43451 nmol/l) were subjected to 120 minutes reperfusion (see Table 1 ).
RESULTS
Every weight rats group initially was compared with other one from three remained groups applying statistical paired t-test (Table 2) . Any emerging significant difference among progesterone levels, will be investigated whether owed in the above-mentioned significant weight correlations. Every progesterone rats group initially was compared with other one from three remainder groups applying statistical paired t-test (see Table 2 ). Applying generalized linear models (GLM) with dependant variable the progesterone levels and independent variables the EPO administration or no, the reperfusion time and their interaction, resulted in: Erythropoietin administ-ration nonsignificantly increased the progesterone levels by 4.235501 nmol/l (-13.07804 nmol/l-21.54904 nmol/l) (p = 0.6233). This finding was in accordance with the results of paired t-test (p = 0.6724). Reperfusion time nonsignificantly decreased the progesterone levels by -0.2034999 Table 2, Table 3 sums up concerning the increasing influence of EPO in connection with reperfusion time. Inserting the rats weight as independent variable at glm, a very significant relation turns on progesterone levels (p = 0.0008), so as to further investigation needs. The predicted progesterone values adjusted for rats weight were calculated and are depicted at Table 4 . The differences between predicted mean progesterone values as calculated by paired t-tests are depicted at Table 5 . Applying GLM with dependant variable the predicted progesterone levels and independent variables the EPO administration or no, the reperfusion time and their interaction, resulted in: erythropoietin administration nonsignificantly decreased the predicted progesterone levels by 3.753567 nmol/l (-12.5406 nmol/l -5.033463 nmol/l) (p = 0.3926). This finding was in accordance with the results of paired t-test (p = 0.3172). Reperfusion time nonsignificantly increased the predicted progesterone levels by 3.753566 nmol/l (-5.033464 nmol/l -12.5406 nmol/l) (p = 0.3926), also in accordance with paired t-test (p = 0.3517). However, EPO administration and reperfusion time together nonsignificantly decreased the predicted progesterone levels by 2.033182 nmol/l (-7.342022 nmol/l -3.275657 nmol/l) (p = 0.4430). Reviewing the above and Tables 5, 6 and 7 sum up concerning the decreasing influence of EPO in connection with reperfusion time.
DISCUSSION
Ulbrich C et al have 1 shown that progesterone (P) applied directly during the first 48 hours after ischemic stroke reduced the infarct volume by more than 70% revealing neuroprotection after 2 weeks. Besides anti-inflammatory and anti-apoptotic actions, angiogenesis in the damaged area appears to be initially affected early after ischemia.
Cutler SM et al exacerbated 2 ischemia suddenly withdrawing progesterone (PW) by repeated dosing after traumatic brain injury (TBI) and stroke in adult male Sprague-Dawley rats. All progesterone treatments resulted in improved molecular recovery. Although progesterone treatment decreases inflammation and apoptosis, only a tapered and not an acute one withdrawal of the hormone further enhances short-term recovery after TBI. Sbarouni E et al did 3 not attenuate shortterm ischemic myocardium protection by the addition of a progestin compound in IR hypercholesterolemic oophorectomized female rabbits. Giannattasio C et al found 4 alterations in radial artery distensibility during the natural menstrual cycle in premenopausal healthy women. The arterial stiffening of the luteal phase depends on vascular smooth muscle contraction due to an endothelial impairment due to an increase in progesterone hormone levels among other phenomena. Ovarian tissue transplantation is used to preserve fertility in patients undergoing chemoradiotherapy. However, IR injury and the production of free radicals occurring during revascularization of the transplanted tissue are the major limitations. The effect of antioxidant drugs in reducing the oxidative stress and improving ovary survival following transplantation is investigated. It is hypothesized that less hypoxemia and less erythropoiesis would occur in the L than the F phase of the cycle at altitude, because the ovarian steroid hormones, progesterone and estrogen, have higher blood levels in the luteal (L) than in the follicular (F) phase of the menstrual cycle since their known effects on ventilation and hematopoiesis. The efficiency of female sex hormone treatment could be related either to the central effects of progesterone and estrogen and/or to the impact of these hormones on erythropoiesis at the kidney/bone marrow level. Steroid metabolites, derived from the in vivo biotransformation of progesterone, are capable in other systems of inducing the synthesis of δ-aminolevulinic acid synthetase, the limiting enzyme in the heme biosynthetic pathway. 10 EpoR levels positively expression with progesterone receptor positivity status and with decreased locoregional disease control in breast cancer patients. Klotz RK et al revealed 11 polyglobulia and a Leydig cell tumor in the hilus and stroma of the left ovary in a 58-year-old woman whose basal laboratory tests were normal for levels of 17alpha-hydroxy-progesterone and EPO. Kwon BK et al reviewed 12 the available neuroprotective therapies including EPO and progesterone administered for acute SCI. Larsson AM et al suggested 13 that EPOR expression in premenopausal women breast cancer affects tumor behavior since high expression of EPOR is related to an impaired tamoxifen response in ER(+)/PR(+) tumors and to improved survival in untreated patients. Pelekanou V et al reported 14 that EPO and membrane-associated receptors for progesterone (mPR) were expressed in 80 and 94% of samples in breast cancer specimens respectively. Significant correlations between EPO-hypoxia-induced mPR-Her2 were found. Schouten JW considered 15 31 that steroid action is independent of EPO and it is suggested that they may play a physiologic role in the regulation of human erythropoiesis.
CONCLUSION
Original and predicted progesterone results are opposite. Predicted results, as more reliable, must be believed. Epo decreases the progesterone levels by 4.7 to 8.8%. This decreasing effect although nonsignificant is reinforced along time. Perhaps, a longer study time than 2 hours may provide clearer and significant effect. 
